Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
about
Replication and Inhibitors of Enteroviruses and ParechovirusesArsenic trioxide sensitivity is associated with low level of glutathione in cancer cellsSusceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolismPotential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyThe glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance.The organotelluride catalyst LAB027 prevents colon cancer growth in the mice.Strategies for reversing drug resistance.Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione.Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligaseDifferential effects of depleting agents on cytoplasmic and nuclear non-protein sulphydryls: a fluorescence image cytometry studyEnhancement of Selectivity of an Organometallic Anticancer Agent by Redox Modulation.Harnessing drug resistance: using ABC transporter proteins to target cancer cells.Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine.PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cellsHuman p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress.Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.The role of 131I-MIBG in high-risk neuroblastoma treatment.The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.Recent trends in cancer drug resistance reversal strategies using nanoparticles.A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: a strange case of Dr. Jekyll and Mr. Hyde.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells.Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi.Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers.Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.Constitutive and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequence.Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death.Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.Survival of rats bearing advanced intracerebral F 98 tumors after glutathione depletion and microbeam radiation therapy: conclusions from a pilot project.An ultrasensitive fluorogenic probe for revealing the role of glutathione in chemotherapy resistance.Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors.
P2860
Q26798463-6F3FCEF3-F501-4AC7-ABE0-EE0BC07422DEQ28343686-A9A087A4-7884-468B-B300-66E1FC3FAFE4Q28484655-83596AB6-C9BA-4B0A-984E-D4C8FC7489CEQ33847525-76C163A6-C6E0-4F6B-AA85-6B45AB0063D3Q33962155-43EEAF7A-9862-45E4-9462-53B5820E9ECAQ34448863-9E4AD8A3-BDEA-4D43-B0D6-397848DCDB11Q35027940-3E20513F-6B78-491F-99D3-8FF7280F0CC1Q35235879-A6561DAA-29F5-44F1-BF89-9297F402CE8AQ35567287-06B8E118-1B89-4FB8-991E-765F89022F95Q35671428-84F6D9EA-4551-4799-8A0E-23F7215EF5CCQ35899265-C62470F0-D947-4B7D-A04C-A6DF33642F43Q36081980-00FF5919-18EA-42A1-95BC-69243DC3508FQ36146681-E25C761A-ADD5-4D69-8082-9A120CB319EBQ36316764-46CE3685-90CA-437B-A95E-54FA9F8A43ECQ36384780-DE46CCCC-D056-45A5-9028-E535A16B47DFQ36502644-FF666510-1EB3-41C2-9337-44A61D1DFE2CQ36738640-ED7B6EA4-FC96-4DAE-B5F9-460ED4D72B9BQ36841921-059FD1DC-A036-4C78-861F-C0BAAD8786A2Q36952837-CF04ACE0-C8DA-4536-B88D-D63C5CB49871Q37131361-B89C46DD-0EF0-44E3-98C5-599292BA1476Q37277121-0A9F10CB-40F8-423C-903E-0ECFDB5EEF60Q37376013-C5A9BDAB-BD8D-4CE9-8AD2-D8C0DAC6A906Q37591069-C4079657-7E5A-4E94-A94A-E4E230441079Q37800633-36620E8C-38A4-4E29-AC66-91A78EAA73E8Q37984588-51FAAFC0-7244-4900-B543-B8C17A4BE08BQ38209675-F5FBE9D0-CF4B-4A2B-BFF4-3272280F803DQ38777221-9AFB2432-F1F5-4FAC-9737-545DFAA6C429Q40316390-5838CB90-44C6-410C-974D-DB51591BCA22Q40582092-39EFB5E8-1304-46F1-818D-247B825AAF9BQ40734322-6DFA6A3E-0F35-43A2-B645-85D2BFD613BDQ41874296-16FF59BF-CA64-439F-9A28-C35451382CF1Q41898218-B92A3AFA-57E7-411F-BD0D-D266AFCD81E4Q42435356-4BD4E987-03BC-465A-8594-CF7DB463E7EDQ44110262-06F78553-EF62-44A0-91C3-20431B573CC4Q46294171-2A42D9E6-6C58-44C3-947A-EB2FEC161483Q46419102-95035D77-4099-4B24-85C0-A1B04C1DA86CQ46842794-21C8A608-5DED-4EE2-B6E7-4053BAD2E00AQ53684485-D2826072-F4C2-4999-AFA9-B9A497576F71Q55024094-25B46F48-BC1B-45B1-8D94-5237FAAB17D5Q55164552-F87B868A-AB1D-40EA-ABCF-0DDA161086BB
P2860
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Phase I clinical trial of intr ...... at modulation of glutathione.
@ast
Phase I clinical trial of intr ...... at modulation of glutathione.
@en
type
label
Phase I clinical trial of intr ...... at modulation of glutathione.
@ast
Phase I clinical trial of intr ...... at modulation of glutathione.
@en
prefLabel
Phase I clinical trial of intr ...... at modulation of glutathione.
@ast
Phase I clinical trial of intr ...... at modulation of glutathione.
@en
P2093
P1476
Phase I clinical trial of intr ...... at modulation of glutathione.
@en
P2093
D R Spriggs
H H Bailey
K D Tutsch
M B Tombes
R T Mulcahy
R Z Arzoomanian
P304
P356
10.1200/JCO.1994.12.1.194
P407
P577
1994-01-01T00:00:00Z